Aduro Biotech Announces Initiation Of Phase 2b ECLIPSE Trial To Evaluate Treatment Of Patients With Pancreatic Cancer With The Company’s Innovative Immunotherapies
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. today announced the initiation of a Phase 2b clinical trial of the company’s immunotherapies GVAX Pancreas and CRS-207. The first patient has been treated in the randomized, controlled, multicenter trial.
Help employers find you! Check out all the jobs and post your resume.